Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series
Introduction: Lung cancer is one of the most common cancers in the world and it is the leading cause of cancer-related deaths, among men and women, in the United States. In advanced non-small cell lung cancers, immune checkpoint inhibitors such as programmed cell death protein-1 inhibitors (PD-1 inh...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Respiratory Medicine Case Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221300711830306X |
id |
doaj-8c9331c01c20472e8bc7782775693043 |
---|---|
record_format |
Article |
spelling |
doaj-8c9331c01c20472e8bc77827756930432020-11-25T01:18:41ZengElsevierRespiratory Medicine Case Reports2213-00712019-01-01261722Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case seriesPadmastuti Akella0Sundaravadivel Loganathan1Vishal Jindal2Jamal Akhtar3Amos Lal4Department of Medicine, Saint Vincent Hospital, 123 Summer Street, Worcester, MA, 01608, United StatesDepartment of Medicine, Saint Vincent Hospital, 123 Summer Street, Worcester, MA, 01608, United StatesDepartment of Medicine, Saint Vincent Hospital, 123 Summer Street, Worcester, MA, 01608, United StatesDepartment of Medicine, Saint Vincent Hospital, 123 Summer Street, Worcester, MA, 01608, United StatesCorresponding author.; Department of Medicine, Saint Vincent Hospital, 123 Summer Street, Worcester, MA, 01608, United StatesIntroduction: Lung cancer is one of the most common cancers in the world and it is the leading cause of cancer-related deaths, among men and women, in the United States. In advanced non-small cell lung cancers, immune checkpoint inhibitors such as programmed cell death protein-1 inhibitors (PD-1 inhibitors) have become second-line therapy and have revolutionized the management in selective cases conferring better overall response rates and progression free survival. Methods: We present a case series and review of literature emphasizing this immune-related adverse events (irAEs) in patients with metastatic non-small cell lung cancer and esophageal cancer who were treated with Nivolumab as a second line therapeutic option. Results: PD-1 inhibitors such as, Nivolumab and Pembrolizumab, have shown a stable regression of various malignancies, such as metastatic melanoma, renal cell carcinoma and metastatic non-small cell lung cancer. We describe 2 cases of such immune related adverse effects associated with immune check point inhibitors with recovery in one of the patients. Steroid therapy has been the cornerstone for treatment for such immune related adverse effects. Importance has also been laid on the typical radiographic patterns of pneumonitis and interstitial lung disease associated with immunotherapy. Conclusions: We attempt to raise awareness, discuss early management strategies and hypothesize an association between the incidence and development of these adverse events in cancer patients treated with anti-PD-1 immunotherapeutic agents.http://www.sciencedirect.com/science/article/pii/S221300711830306X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Padmastuti Akella Sundaravadivel Loganathan Vishal Jindal Jamal Akhtar Amos Lal |
spellingShingle |
Padmastuti Akella Sundaravadivel Loganathan Vishal Jindal Jamal Akhtar Amos Lal Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series Respiratory Medicine Case Reports |
author_facet |
Padmastuti Akella Sundaravadivel Loganathan Vishal Jindal Jamal Akhtar Amos Lal |
author_sort |
Padmastuti Akella |
title |
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series |
title_short |
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series |
title_full |
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series |
title_fullStr |
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series |
title_full_unstemmed |
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series |
title_sort |
anti pd-1 immunotherapy related interstitial lung disease presenting as respiratory failure - a review with case series |
publisher |
Elsevier |
series |
Respiratory Medicine Case Reports |
issn |
2213-0071 |
publishDate |
2019-01-01 |
description |
Introduction: Lung cancer is one of the most common cancers in the world and it is the leading cause of cancer-related deaths, among men and women, in the United States. In advanced non-small cell lung cancers, immune checkpoint inhibitors such as programmed cell death protein-1 inhibitors (PD-1 inhibitors) have become second-line therapy and have revolutionized the management in selective cases conferring better overall response rates and progression free survival. Methods: We present a case series and review of literature emphasizing this immune-related adverse events (irAEs) in patients with metastatic non-small cell lung cancer and esophageal cancer who were treated with Nivolumab as a second line therapeutic option. Results: PD-1 inhibitors such as, Nivolumab and Pembrolizumab, have shown a stable regression of various malignancies, such as metastatic melanoma, renal cell carcinoma and metastatic non-small cell lung cancer. We describe 2 cases of such immune related adverse effects associated with immune check point inhibitors with recovery in one of the patients. Steroid therapy has been the cornerstone for treatment for such immune related adverse effects. Importance has also been laid on the typical radiographic patterns of pneumonitis and interstitial lung disease associated with immunotherapy. Conclusions: We attempt to raise awareness, discuss early management strategies and hypothesize an association between the incidence and development of these adverse events in cancer patients treated with anti-PD-1 immunotherapeutic agents. |
url |
http://www.sciencedirect.com/science/article/pii/S221300711830306X |
work_keys_str_mv |
AT padmastutiakella antipd1immunotherapyrelatedinterstitiallungdiseasepresentingasrespiratoryfailureareviewwithcaseseries AT sundaravadivelloganathan antipd1immunotherapyrelatedinterstitiallungdiseasepresentingasrespiratoryfailureareviewwithcaseseries AT vishaljindal antipd1immunotherapyrelatedinterstitiallungdiseasepresentingasrespiratoryfailureareviewwithcaseseries AT jamalakhtar antipd1immunotherapyrelatedinterstitiallungdiseasepresentingasrespiratoryfailureareviewwithcaseseries AT amoslal antipd1immunotherapyrelatedinterstitiallungdiseasepresentingasrespiratoryfailureareviewwithcaseseries |
_version_ |
1725141131445927936 |